A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to ...

Gynecologic clear cell cancers are aggressive malignant neoplasms with low response rates to chemotherapy. Among patients ...

Genetic testing revealed that she was positive for BRCA1, a genetic mutation that increases one’s risk of breast and ovarian ...

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to ...

In recent years, the analysis of single-cell and spatial data has revolutionized biomedical research, making it possible to ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without ...

Model includes age, body mass index, hypertriglyceridemia, tumor staging, tumor grade, CA125 level, platelet count, fibrinogen level.

Between 35% to 40% of ovarian cancer patients express high levels of FRα (i.e. greater than or equal to 75% tumour cells staining with 2+ intensity).

Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

Medical news, education and information for physicians and health care professionals, presented by specialty and topic. From Healio and the Wyanoke Group.